{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HU+-+Hydroxyurea",
    "query": {
      "intervention": "HU - Hydroxyurea"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HU+-+Hydroxyurea&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T11:54:34.622Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05405114",
      "title": "Research Study Investigating How Well NDec Works in People With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "NDec - oral decitabine-tetrahydrouridine",
          "type": "DRUG"
        },
        {
          "name": "HU - Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2022-07-07",
      "completion_date": "2025-07-24",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 53,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405114"
    },
    {
      "nct_id": "NCT00002427",
      "title": "Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Institute for Genetic and Human Therapy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "1999-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002427"
    },
    {
      "nct_id": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Leukemia, Myelocytic, Acute",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic Syndrome (MDS)",
        "Preleukemia",
        "Primary Myelofibrosis",
        "Myeloproliferative Disorders",
        "Bone Marrow Disease",
        "Hematological Disease",
        "Precancerous Conditions",
        "Neoplasms",
        "Leukemia",
        "Neoplasms by Histologic Type",
        "Essential Thrombocytosis"
      ],
      "interventions": [
        {
          "name": "Pelabresib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Constellation Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2014-07-16",
      "completion_date": "2025-01-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02158858"
    },
    {
      "nct_id": "NCT00383448",
      "title": "HSCT for High Risk Inherited Inborn Errors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenoleukodystrophy",
        "Metachromatic Leukodystrophy",
        "Globoid Cell Leukodystrophy",
        "Tay Sachs Disease",
        "Sandhoffs Disease",
        "Wolman Disease",
        "I-Cell Disease",
        "Sanfilippo Syndrome",
        "GM1 Gangliosidosis"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Total body Irradiation",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "mycophenylate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine A",
          "type": "DEVICE"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 38,
      "start_date": "2006-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383448"
    },
    {
      "nct_id": "NCT05421104",
      "title": "Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycythemia Vera (PV)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1576,
      "start_date": "2020-11-27",
      "completion_date": "2021-06-29",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05421104"
    },
    {
      "nct_id": "NCT01847326",
      "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "hyperfractionated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2013-03-26",
      "completion_date": "2024-01-22",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847326"
    },
    {
      "nct_id": "NCT01597401",
      "title": "A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Aes-103",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-05-12",
      "completion_date": "2013-06-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597401"
    },
    {
      "nct_id": "NCT01506544",
      "title": "Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-12-12",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01506544"
    },
    {
      "nct_id": "NCT03442114",
      "title": "Shared-Decision Making for Hydroxyurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Children, Only"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea SDM Toolkit",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Pocket Guide",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "1 Month to 5 Years"
      },
      "enrollment_count": 176,
      "start_date": "2018-07-12",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 11,
      "location_summary": "Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03442114"
    },
    {
      "nct_id": "NCT03077542",
      "title": "Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "haploidentical stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 57,
      "start_date": "2017-04-06",
      "completion_date": "2026-08-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-05T11:54:34.622Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03077542"
    }
  ]
}